Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Angiogenesis Therapy
10%
Angiogenic Cytokines
10%
Anticoagulants
10%
Arteriogenesis
100%
Assure
10%
Cardiovascular Mortality
10%
Cell Therapy
20%
Chronic Ischemia
10%
Claudication
10%
Clinical Consequences
10%
Comorbid Conditions
10%
Conduit Artery
10%
Distal Limb
20%
Endovascular Procedures
10%
Expected Rate
10%
Functional Capacity
10%
Gene Therapy
10%
Large Arteries
10%
Limb Events
10%
Limb Salvage
10%
Lipid-lowering
10%
Lower Limb Amputation
10%
Major Adverse Cardiovascular Events
10%
Medical Therapy
20%
Microvascular Disease
10%
Myocardial Infarction
10%
Obstructive Disease
10%
Pain at Rest
10%
Perfusion
10%
Peripheral Arterial Disease
100%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
10%
Randomized Clinical Trial
10%
Recombinant Protein
10%
Revascularization
20%
Rivaroxaban
10%
Significant Benefit
10%
Surgical Procedures
10%
Therapeutic Angiogenesis
100%
Tissue Integrity
10%
United States
10%
Medicine and Dentistry
Angiogenesis
100%
Antithrombotic
10%
Apoplexy
10%
Arteriogenesis
100%
Arteriosclerosis Obliterans
100%
Cardiovascular System
20%
Cell Therapy
20%
Claudication
10%
Combination Therapy
20%
Cytokine
10%
Diseases
10%
Endovascular Surgery
10%
Functional Status
10%
Gene Therapy
10%
Ischemia
10%
Leg Amputation
10%
Limb
50%
Limb Salvage
10%
Microangiopathy
10%
Myocardial Infarction
10%
Obstruction
10%
Prevalence
10%
Proprotein Convertase 9
10%
Randomized Clinical Trials
10%
Recombinant Protein
10%
Revascularization
20%
Rivaroxaban
10%
Surgical Technique
10%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
10%
Cerebrovascular Accident
10%
Claudication
10%
Combination Therapy
20%
Cytokine
10%
Diseases
10%
Functional Status
10%
Heart Infarction
10%
Ischemia
10%
Microangiopathy
10%
Obstruction
10%
Peripheral Occlusive Artery Disease
100%
Prevalence
10%
Proprotein Convertase 9
10%
Randomized Clinical Trial
10%
Recombinant Protein
10%
Rivaroxaban
10%